Raft Of Chinese Pharmas Join Active Financing Market
This article was originally published in PharmAsia News
December has been a busy financing month for the pharmaceutical industry in China, the key takeaways from the hectic activity being a series of major fundraisings and a trend for pharma companies from mainland China to tap into the active Hong Kong stock market through IPOs.
You may also be interested in...
ARCH invests $150m in the Scangos-led Vir Biotechnology; Flagship recruits ex-Novartis executive Epstein; Versant closes a new $400m fund; and $601.1m in 11 other recent VC funding rounds.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.